Klajdi, our CEO at Luminary Group, will be attending the World Drug Safety Congress Europe from 09-10 October. If you'd like to grab 5-10 minutes with Klajdi to discuss potential collaborations or share insights, feel free to reach out and connect. It’s a great opportunity to explore new ideas and strengthen relationships in the industry. Luminary Group has positioned itself as a leader in the consulting space, specializing in placing top executives and offering tailored commercial, operational, and outsourcing solutions for pharmaceutical companies in niche areas such as pharmacovigilance and regulatory affairs across Europe, the USA, and APAC. We are excited to meet with our industry partners and peers at the event. Looking forward to seeing you all there! #WDSC #pharmacovigilance #pharma #regulatory #compliance #pv #lifescience #healthcare #consulting #amsterdam #netherlands #worlddrugsafetyeurope #worlddrugsafety
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
-
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗩𝗖 𝗳𝗶𝗿𝗺 𝘁𝗮𝗿𝗴𝗲𝘁𝘀 $𝟯𝟱𝗠 𝘀𝗲𝗰𝗼𝗻𝗱 𝗳𝘂𝗻𝗱 𝘁𝗼 𝗯𝗮𝗰𝗸 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝗹𝗲𝗱 𝗯𝘆 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 A small venture capital firm that backs up-and-coming scientists plans to raise a $35 million second fund, three years after coming onto the scene. … https://lnkd.in/dkxvVzKV
-
𝗜𝗺𝗺𝗮𝘁𝗶𝗰𝘀 𝗵𝗲𝗮𝗱𝘀 𝘁𝗼 𝗣𝗵𝗮𝘀𝗲 𝟯 𝘄𝗶𝘁𝗵 𝗺𝗲𝗹𝗮𝗻𝗼𝗺𝗮 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆, 𝘀𝗲𝗲𝗸𝘀 𝘁𝗼 𝗿𝗮𝗶𝘀𝗲 $𝟭𝟱𝟬𝗠 Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an early-stage trial, and … https://lnkd.in/dS7588F8
Immatics heads to Phase 3 with melanoma cell therapy, seeks to raise $150M
endpts.com
-
𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝗨𝗽𝘀𝘁𝗿𝗲𝗮𝗺 𝗮𝗻𝗱 𝗖𝗔𝗠𝗣𝟰 𝗽𝗿𝗶𝗰𝗲 𝗙𝗿𝗶𝗱𝗮𝘆 𝗜𝗣𝗢𝘀 Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in what appears to be a … https://lnkd.in/dcgFNFdu
Biotech startups Upstream and CAMP4 price Friday IPOs
endpts.com
-
𝗥𝗲𝗲𝗺𝗮 𝗛𝗲𝗮𝗹𝘁𝗵 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟳.𝟲𝗠 𝘁𝗼 𝗿𝗲𝗮𝗰𝗵 𝗽𝗲𝗼𝗽𝗹𝗲 𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗮𝗶𝗱 A startup that helps community workers guide Medicaids Pharma members to the care they need just raised a new round of funding. People on government-run Medicaid …Richard Lungen ,Justin Ley https://lnkd.in/gWVt2aSK
Exclusive: Reema Health raises $7.6M to reach people on Medicaid
endpts.com
-
𝗖𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗱𝗿𝘂𝗴𝘀 𝗰𝗼𝘂𝗹𝗱 𝗰𝗼𝘀𝘁 𝗠𝗲𝗱𝗶𝗰𝗮𝗿𝗲 $𝟯𝟱𝗕 𝗯𝘆 𝟮𝟬𝟯𝟰, 𝗖𝗕𝗢 𝘀𝗮𝘆𝘀 While Win-Medicare Pvt. Ltd. doesn’t currently cover anti-obesity drugs, a new report from the Congressional Budget Office estimates that coverage could cost Medicare $35 billion from 2026 … https://lnkd.in/dyd-4arM
Covering obesity drugs could cost Medicare $35B by 2034, CBO says
endpts.com
-
𝗖𝗠𝗦 𝗹𝗼𝗼𝗸𝘀 𝘁𝗼 $𝟮 𝗼𝘂𝘁-𝗼𝗳-𝗽𝗼𝗰𝗸𝗲𝘁 𝗰𝗮𝗽 𝗳𝗼𝗿 𝘀𝗼𝗺𝗲 𝗰𝗼𝗺𝗺𝗼𝗻𝗹𝘆 𝘂𝘀𝗲𝗱 𝗴𝗲𝗻𝗲𝗿𝗶𝗰 𝗱𝗿𝘂𝗴𝘀 The Centers for Medicare & Medicaid Services on Wednesday published a list of 101 commonly used generic medicines that would cost some Medicare patients no … https://lnkd.in/emegRCxu
CMS looks to $2 out-of-pocket cap for some commonly used generic drugs
endpts.com
-
𝗭𝗲𝗮𝗹𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮 𝗵𝗶𝘁 𝘄𝗶𝘁𝗵 𝘀𝗲𝗰𝗼𝗻𝗱 𝗖𝗥𝗟 𝗳𝗼𝗿 𝗴𝗹𝘂𝗰𝗮𝗴𝗼𝗻 𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗮𝗴𝗼𝗻𝗶𝘀𝘁 The FDA handed down a second complete response letter to Zealand Pharma for its glucagon receptor agonist in an ultra-rare genetic disease called congenital hyperinsulinism … https://lnkd.in/dAUstrwG
Zealand Pharma hit with second CRL for glucagon receptor agonist
endpts.com
-
𝗕𝗮𝘀𝗲𝗰𝗮𝗺𝗽 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟲𝟬𝗠 𝘁𝗼 𝘁𝗿𝗮𝘃𝗲𝗹 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗲 𝗮𝗻𝗱 𝗳𝗶𝗹𝗹 𝗔𝗜 𝗱𝗮𝘁𝗮 𝗴𝗮𝗽𝘀, 𝘀𝗶𝗴𝗻𝘀 𝗱𝗲𝗮𝗹 𝘄𝗶𝘁𝗵 𝗗𝗮𝘃𝗶𝗱 𝗟𝗶𝘂 London-based startup Basecamp Research has closed a $60 million Series B round that will help expand its genomic database and what it sees as gaps …Glen Gowers, Oliver Vince https://lnkd.in/d6k27mmW
Basecamp raises $60M to travel the globe and fill AI data gaps, signs deal with David Liu
endpts.com
-
𝗣𝘂𝗿𝗲𝘀𝗽𝗿𝗶𝗻𝗴 𝗻𝗮𝗯𝘀 $𝟭𝟬𝟱𝗠 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗰𝗹𝗶𝗻𝗶𝗰 𝗮𝘀 𝗜𝗴𝗔𝗡 𝗳𝗶𝗲𝗹𝗱 𝗺𝗮𝘁𝘂𝗿𝗲𝘀 Purespring Therapeutics has reeled in £80 million ($105 million) to test two gene therapies in humans. The Sofinnova Partners-led Series B, disclosed Wednesday morning, will … https://lnkd.in/d2ams6DW
Purespring nabs $105M to take gene therapy into the clinic as IgAN field matures
endpts.com